

Impact Report: 2025

ADVANCING INNOVATION TO SAVE LIVES



www.ghtcoalition.org

The Global Health Technologies Coalition (GHTC) is committed to advancing policies to accelerate the creation of new drugs, vaccines, diagnostics, and other tools that bring healthy lives within reach for all people worldwide. We advocate for the US government and multilateral entities to enact policies and commit resources to catalyze development of new technologies to address the world's most pressing health challenges.

This report summarizes the coalition's impact and collective efforts in 2025.



Clockwise from top: Architect of the Capitol; PATH/Georgina Goodwin; GHTC.





136

congressional meetings



88

meetings with US agency
& multilateral officials



675

US appropriations report language
requests submitted



277

pieces of evidence provided
to policymakers & influencers



13

educational & advocacy
resources created



75

blog posts, including
51 weekly R&D news roundups
& 24 original pieces

Protected Global Health R&D Funding

OUR WIN

Influenced Congress to advance interim fiscal year 2026 (FY26) funding bills rejecting deep cuts to global health R&D accounts and moderate a summer rescissions package proposing further cuts to key programs, ultimately protecting funding for the US President's Emergency Plan for AIDS Relief and preserving investments in malaria, tuberculosis, and maternal and child health.

PHOTO: GHTC co-organized an in-district event with Rep. Mario Diaz-Balart, Chairman of the National Security, State and Related Programs Appropriations Subcommittee to highlight the local benefits of global health R&D investments.

GHTC

WHAT IT TOOK

While Congress has yet to pass a full FY26 budget, GHTC's advocacy shaped interim [House](#) and [Senate bills](#) that largely rejected proposed funding reductions for global health programs at the Department of State, the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Biomedical Advanced Research and Development Authority (BARDA), including elimination of the NIH Fogarty International Center and CDC Global Health Center. These bills also featured [GHTC-advanced report language](#) supporting [R&D activities](#) across [agencies](#).

To achieve this, GHTC delivered [testimony](#) and [letters](#), shaped member Dear Colleague letters and [testimony](#), and submitted a record 675 report language requests to 91 congressional offices.



We organized a Hill Day with GHTC members focused on appropriations and conducted 76 appropriations-related Hill meetings. We also coordinated broader community advocacy through the Global Health Council, released new fact sheets on [CDC global health](#)

[activities](#) and the [Fogarty International Center](#), co-led a Global Friends of CDC Hill Day, and co-organized district level events with Representatives Mario Diaz-Balart (R-FL) and Young Kim (R-CA) to highlight the local economic and public health benefits of US global health R&D investments.

In response to rescissions proposals, GHTC joined broader community efforts, conducted direct outreach to Senate Republicans, and equipped members with templates and talking points to support targeted congressional engagement.

Raised Awareness of Foreign Aid Freeze Impacts and Advanced Efforts to Rebuild Health R&D at State

OUR WIN


Educated and activated Congress on the detrimental impacts of the foreign aid suspension and US Agency for International Development (USAID) award terminations on health R&D, while advancing efforts to rebuild global health R&D programming within the State Department. These efforts helped advance House report language encouraging State to continue health R&D activities and likely informed elements of the new [US global health strategy](#) that create an opening for the agency to support breakthrough technologies and explore the creation of a new innovation-focused fund.

PHOTO: GHTC members advocate for rebuilding global health R&D programming at the State Department during the coalition's fall Hill Day.

GHTC

WHAT IT TOOK

Following the foreign assistance funding pause, GHTC swiftly documented the impacts on health R&D and shared our findings privately with key congressional offices and reporters, while equipping members with [messaging](#) aligned with the evolving priorities of the administration. Although Congress had limited tools to intervene directly, these efforts contributed to lawmakers publicly raising concerns in [hearings](#) and [letters](#) and [shaped media coverage](#).



Following USAID's integration into State, GHTC advocated with Congress and the administration to reestablish health R&D programming at State, meeting with senior State officials ahead of the strategy's release and later engaging on the concept of an innovation fund. We also advanced a GHTC-proposed [amendment](#) to a House State reauthorization bill to authorize the department to carry out former USAID global health R&D functions. While the amendment narrowly failed (25–26), it garnered bipartisan support and helped lay the groundwork for report language encouraging State to continue health R&D activities, an important step toward establishing congressional expectations for State's role in this area. Over the 2025 December holiday break, however, the report was pulled back indefinitely and will not be released publicly.

Secured NIH Foreign Subaward Policy Exemption and Elevated Other Critical Issues Across NIH, BARDA, and CDC

OUR WIN

Influenced NIH to clarify an [exemption](#) to its [new foreign subaward policy](#), allowing existing awards involving human subjects research to continue uninterrupted until the new award system is implemented, as well as elevated concerns about other policy actions affecting NIH, BARDA, and CDC programs.

WHAT IT TOOK

Recognizing the NIH policy was unlikely to be reversed, GHTC and partners focused on securing exemptions and clarifying guidance to minimize disruptions to critical ongoing research. This effort included repeated meetings with NIH officials and a [co-signed letter](#) to the NIH Director outlining impacts and recommending mitigation actions.

Beyond NIH, GHTC pressed for the reinstatement at State of a former CDC–USAID interagency agreement supporting CDC global malaria programming, prompting congressional outreach to State Department officials, though broader political dynamics have thus far limited resolution. In response to BARDA's wind-down of mRNA vaccine research, we educated congressional offices on programmatic impacts and urged engagement and oversight. More broadly, as congressional staff navigated a high volume of executive actions with limited agency transparency, GHTC served as a trusted resource of timely analysis, conducting 60 additional Hill meetings beyond appropriations and 58 agency meetings to convey the impacts of this pullback in funding and share intelligence.




PHOTO: Researchers participate in an African research workforce training initiative supported by the NIH Fogarty International Center.

Courtesy of Fogarty International Center

Influenced Adoption of Pandemic Agreement and Shaped G20

OUR WIN

Helped [embed R&D](#) as a core component of the historic [Pandemic Agreement](#) adopted at the World Health Assembly (WHA) and influenced G20 negotiations to elevate health R&D on the agenda. These engagements reinforced the importance of sustained R&D investment as a core pillar of global health security and preparedness.

PHOTO: The Pandemic Accord is officially adopted at the 78th World Health Assembly in Geneva, Switzerland, on May 20, 2025.

Courtesy of WHO/Pierre Albouy

WHAT IT TOOK

Throughout the Pandemic Agreement negotiations, GHTC worked with partners to advocate for robust R&D and equitable access provisions. After its adoption, we contextualized its [implications](#) and pivoted to try to [influence](#) follow-on negotiations on the Pathogen



Access and Benefit Sharing System. On G20, while political tensions ultimately prevented a health ministerial communiqué, R&D language and commitments advanced by GHTC—including on antimicrobial resistance and the Brazilian-led Global Coalition for Local and Regional

Production, Innovation and Equitable Access—featured in [interim draft communiqués](#) and an [unofficial chairman's summary](#), and the [Leaders' Declaration](#) voiced support for broader R&D-relevant initiatives and international scientific partnerships.

In addition, GHTC shaped recommendations [adopted by the G20 Research and Innovation Ministers' Working Group](#) on boosting science capacity and cultivating community-based science spaces. GHTC elevated our [R&D priorities](#) through [C20 policy recommendations](#), via our leadership role as cochair of a C20 working group and through other partners, [influencing reports](#), leading a sign-on letter, [cohosting](#) and [speaking](#) at events, and engaging directly with the South African presidency. On the broader issue of global health security, we also continued to chair the [Global Health Security Agenda's R&D Task Force](#), leveraging the platform to convene important dialogues with the Pandemic Fund, the International Atomic Energy Agency, and the World Health Organization (WHO) mRNA Technology Transfer Hub, furthering discussion and analysis of [R&D-related investments](#) by the Pandemic Fund.

Advanced WHO Actions on PQ, Clinical Trials, and Climate and Health

OUR WIN

Advanced WHO implementation of the new [parallel prequalification \(PQ\) and policy guidance processes](#) for tuberculosis diagnostics, adoption of a [global action plan on clinical trial strengthening](#) and launch of the [Global Clinical Trials Forum](#) to advance implementation, and inclusion of strong R&D components in the first-ever [Climate and Health Action Plan](#).

WHAT IT TOOK

GHTC maintained steady pressure on the PQ program to continue to implement operational improvements through a high-level meeting with the head of the program, our new [PQ Pulse](#) interview series [spotlighting challenges](#) and opportunities, and an updated [PQ Scorecard](#). On clinical trials, we shaped the [action plan](#), which includes provisions on the inclusion of underserved populations in clinical research, through technical input and direct engagement with decision-makers, building on prior GHTC advocacy that led to the [2022 WHA resolution](#) on clinical trials. We also contributed input in the [forum's](#) design phase and supported PATH's (as GHTC's secretariat) successful membership application, positioning GHTC and its members for continued technical and policy influence. For climate and health, we advocated for R&D provisions through civil society statements and engagements at the WHO [Executive Board](#) meeting and [WHA](#). Alongside these wins, GHTC tracked the [impacts](#) of the WHO reorganization, cohosted a WHA [side event on sustainable financing](#), and provided timely WHA updates to members during the convening.



PHOTO: GHTC's Senior Multilateral Policy and Advocacy Officer Philip Kenol facilitates a panel discussion on the future of financing for global health R&D on the sidelines of WHA.

GHTC

Launched New Member Services and Navigated Political Change

OUR WIN

Launched new members-only services, including a speaker series, and provided timely, contextualized intelligence to help our community navigate a rapidly shifting and often opaque policy environment.

WHAT IT TOOK

GHTC convened high-level member dialogues with leaders, including Dr. Jeremy Farrar, Assistant Director General of Health Promotion, Disease Prevention and Control at WHO; Senate Appropriations staffers; Priya Basu, Executive Head of the Pandemic Fund; Lou Valdez, Deputy Director of the Pan American Health Organization; and more. Amid rapid US policy changes and limited transparency, we gathered intelligence and contextualized the impacts for our members, maintaining an [executive action tracker](#) during the administration's first 100 days and providing weekly policy updates throughout the year.



We also responded to more than a dozen speaking requests and invites to contribute our expertise to civil society forums and published 75 blog posts, including 51 weekly summaries of top global health R&D news and 24 original pieces spotlighting critical global health R&D issues. These services were designed to ensure members could act quickly, strategically, and with confidence amid uncertainty.

PHOTO: GHTC Executive Director Dr. Kristie Mikus speaks at an event at the World Health Summit.

GHTC

The Global Health Technologies Coalition (GHTC) works to save and improve lives by encouraging the research and development of essential health technologies.

We bring together more than 45 nonprofit organizations, academic institutions, and aligned businesses to advance policies to accelerate the creation of new drugs, vaccines, diagnostics, and other tools that bring healthy lives within reach for all people.



www.ghtcoalition.org